These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 20977290)
21. Melts of Octaacetyl Sucrose as Oral-Modified Release Dosage Forms for Delivery of Poorly Soluble Compound in Stable Amorphous Form. Haznar-Garbacz D; Kaminska E; Zakowiecki D; Lachmann M; Kaminski K; Garbacz G; Dorożyński P; Kulinowski P AAPS PharmSciTech; 2018 Feb; 19(2):951-960. PubMed ID: 29098644 [TBL] [Abstract][Full Text] [Related]
22. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets. Walsh PL; Bothe JR; Bhardwaj S; Hu M; Nofsinger R; Xia B; Persak S; Pennington J; Bak A Drug Dev Ind Pharm; 2016; 42(5):836-44. PubMed ID: 26339722 [TBL] [Abstract][Full Text] [Related]
23. Biorelevant in vitro performance testing of orally administered dosage forms-workshop report. Reppas C; Friedel HD; Barker AR; Buhse LF; Cecil TL; Keitel S; Kraemer J; Morris JM; Shah VP; Stickelmeyer MP; Yomota C; Brown CK Pharm Res; 2014 Jul; 31(7):1867-76. PubMed ID: 24643933 [TBL] [Abstract][Full Text] [Related]
24. Development of a bio-relevant dissolution test device simulating mechanical aspects present in the fed stomach. Koziolek M; Görke K; Neumann M; Garbacz G; Weitschies W Eur J Pharm Sci; 2014 Jun; 57():250-6. PubMed ID: 24051217 [TBL] [Abstract][Full Text] [Related]
25. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles. Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788 [TBL] [Abstract][Full Text] [Related]
26. Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions. Garbacz G; Rappen GM; Koziolek M; Weitschies W J Pharm Pharmacol; 2015 Feb; 67(2):199-208. PubMed ID: 25557626 [TBL] [Abstract][Full Text] [Related]
27. Physiologically Based In vitro Models to Predict the Oral Dissolution and Absorption of a Solid Drug Delivery System. Li Z; He X Curr Drug Metab; 2015; 16(9):777-806. PubMed ID: 26264200 [TBL] [Abstract][Full Text] [Related]
28. Two- and three-layer tablet drug delivery systems for oral sustained release of soluble and poorly soluble drugs. Efentakis M; Naseef H; Vlachou M Drug Dev Ind Pharm; 2010 Aug; 36(8):903-16. PubMed ID: 20196641 [TBL] [Abstract][Full Text] [Related]
29. Designing a dynamic dissolution method: a review of instrumental options and corresponding physiology of stomach and small intestine. Culen M; Rezacova A; Jampilek J; Dohnal J J Pharm Sci; 2013 Sep; 102(9):2995-3017. PubMed ID: 23494815 [TBL] [Abstract][Full Text] [Related]
30. Selection of the most suitable dissolution method for an extended release formulation based on IVIVC level A obtained on cynomolgus monkey. Scheubel E; Adamy L; Hoffart V; Cardot JM Drug Dev Ind Pharm; 2010 Nov; 36(11):1320-9. PubMed ID: 20849348 [TBL] [Abstract][Full Text] [Related]
31. Modelling drug dissolution from controlled release products using genetic programming. Do DQ; Rowe RC; York P Int J Pharm; 2008 Mar; 351(1-2):194-200. PubMed ID: 18053658 [TBL] [Abstract][Full Text] [Related]
32. In vitro models for the prediction of in vivo performance of oral dosage forms. Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843 [TBL] [Abstract][Full Text] [Related]
33. Use of biorelevant media for assessment of a poorly soluble weakly basic drug in the form of liquisolid compacts: in vitro and in vivo study. Badawy MA; Kamel AO; Sammour OA Drug Deliv; 2016; 23(3):818-27. PubMed ID: 24892630 [TBL] [Abstract][Full Text] [Related]
34. Geometry of modified release formulations during dissolution--influence on performance of dosage forms with diclofenac sodium. Dorożyński P; Kulinowski P; Jamróz W; Juszczyk E Int J Pharm; 2014 Dec; 477(1-2):57-63. PubMed ID: 25311175 [TBL] [Abstract][Full Text] [Related]
35. Drug release from matrix tablets: physiological parameters and the effect of food. Nokhodchi A; Asare-Addo K Expert Opin Drug Deliv; 2014 Sep; 11(9):1401-18. PubMed ID: 24970101 [TBL] [Abstract][Full Text] [Related]
36. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270 [TBL] [Abstract][Full Text] [Related]
38. Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model. Karkossa F; Krueger A; Urbaniak J; Klein S AAPS PharmSciTech; 2017 Feb; 18(2):309-316. PubMed ID: 27909943 [TBL] [Abstract][Full Text] [Related]
39. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. Kleberg K; Jacobsen J; Müllertz A J Pharm Pharmacol; 2010 Nov; 62(11):1656-68. PubMed ID: 21039549 [TBL] [Abstract][Full Text] [Related]
40. AC biosusceptometry in the study of drug delivery. Corá LA; Romeiro FG; Stelzer M; Américo MF; Oliveira RB; Baffa O; Miranda JR Adv Drug Deliv Rev; 2005 Jun; 57(8):1223-41. PubMed ID: 15935871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]